Product Licensing

Pharma company licenses novel anticancer compounds

Published in Cancer Weekly, March 22nd, 2005

Prolexys Pharmaceuticals, Inc., announced that it has signed an exclusive licensing agreement with the Massachusetts Institute of Technology, acting as licensing agent for the Whitehead Institute for Biomedical Research of Cambridge, Massachusetts, and Columbia University of New York City.

The agreement provides Prolexys with exclusive, worldwide rights to a patent estate covering selective antitumor compounds discovered by Dr. Brent Stockwell, a former Whitehead Fellow, now an assistant professor of Biological Sciences and Chemistry at Columbia University.

Additional intellectual property was developed by Stockwell and scientists at Prolexys as part...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-03-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry